Menu Search
Equities

Medicofarma Biotech SA

MDB:WSE

Medicofarma Biotech SA

Actions
  • Price (PLN)0.558
  • Today's Change0.036 / 6.90%
  • Shares traded5.11k
  • 1 Year change-56.41%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in PLNIncome statement in PLNView more

Year on year Medicofarma Biotech SA's revenues fell -82.34% from 4.25m to 750.81k. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 1.59m to a larger loss of 3.44m.
Gross margin81.92%
Net profit margin-199.65%
Operating margin-203.88%
Return on assets-17.87%
Return on equity-27.15%
Return on investment-23.82%
More ▼

Cash flow in PLNView more

In 2023, cash reserves at Medicofarma Biotech SA fell by 502.33k. Cash Flow from Financing totalled 596.70k or 79.47% of revenues. In addition the company generated 7.26k in cash from operations while cash used for investing totalled 1.11m.
Cash flow per share-0.015
Price/Cash flow per share--
Book value per share0.128
Tangible book value per share0.1262
More ▼

Balance sheet in PLNView more

Medicofarma Biotech SA uses little or no debt in its capital structure.
Current ratio0.8404
Quick ratio0.8394
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.